• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Inari Medical Inc.

    11/7/24 4:49:55 PM ET
    $NARI
    Medical/Dental Instruments
    Health Care
    Get the next $NARI alert in real time by email
    SC 13G/A 1 d867443dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    Inari Medical, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    45332Y109

    (CUSIP Number)

    February 29, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d–1(b)

     

    ☐

    Rule 13d–1(c)

     

    ☒

    Rule 13d–1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 45332Y109

     

     (1)   

     Names of reporting persons

     

     CVF, LLC

     (2)  

     Check the appropriate box if a member of a group (see instructions)

     

     (a) ☐  (b) ☐

     (3)  

     SEC use only

     

     (4)  

     Citizenship or place of organization

     

     Delaware

    Number of

    shares

    beneficially 

    owned by

    each

    reporting

    person

    with:

       (5)   

     Sole voting power

     

       (6)  

     Shared voting power

     

     2,914,246

       (7)  

     Sole dispositive power

     

       (8)  

     Shared dispositive power

     

     2,914,246

     (9)   

     Aggregate amount beneficially owned by each reporting person

     

     2,914,246

    (10)  

     Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

    (11)  

     Percent of class represented by amount in Row (9)

     

     5.0%

    (12)  

     Type of reporting person (see instructions)

     

     OO


    CUSIP No. 45332Y109

     

     (1)   

     Names of reporting persons

     

     HCC Manager LLC

     (2)  

     Check the appropriate box if a member of a group (see instructions)

     

     (a) ☐  (b) ☐

     (3)  

     SEC use only

     

     (4)  

     Citizenship or place of organization

     

     Illinois

    Number of

    shares

    beneficially 

    owned by

    each

    reporting

    person

    with:

       (5)   

     Sole voting power

     

       (6)  

     Shared voting power

     

     2,914,246

       (7)  

     Sole dispositive power

     

       (8)  

     Shared dispositive power

     

     2,914,246

     (9)   

     Aggregate amount beneficially owned by each reporting person

     

     2,914,246

    (10)  

     Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

    (11)  

     Percent of class represented by amount in Row (9)

     

     5.0%

    (12)  

     Type of reporting person (see instructions)

     

     HC


       SCHEDULE 13G    Page ___ of ___

    Item 1(a) Name of issuer: Inari Medical, Inc.

    Item 1(b) Address of issuer’s principal executive offices: 6001 Oak Canyon, Suite 100, Irvine, California 92618

    2(a) Name of person filing:

    CVF, LLC (“CVF”)

    2(b) Address or principal business office or, if none, residence:

    222 N. LaSalle Street, Suite 2000, Chicago, Illinois 60601

    2(c) Citizenship:

    Delaware

    2(d) Title of class of securities:

    Common Stock, $0.001 par value per share

    2(e) CUSIP No.:

    45332Y109

    2(a) Name of person filing:

    HCC Manager LLC (“HCC”)

    2(b) Address or principal business office or, if none, residence:

    222 N. LaSalle Street, Suite 2000, Chicago, Illinois 60601

    2(c) Citizenship:

    Illinois

    2(d) Title of class of securities:

    Common Stock, $0.001 par value per share

    2(e) CUSIP No.: 45332Y109

     

    Item 3.

    If this statement is filed pursuant to §§240.13d–1(b) or 240.13d–2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a–8);
    (e)    ☐    An investment adviser in accordance with §240.13d–1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d–1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with §240.13d–1(b)(1)(ii)(G);


    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a–3);
    (j)    ☐    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with §240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned: See row 9 of the cover page.

    (b) Percent of class: See row 11 of the cover page.

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote See row 5 of the cover page.

    (ii) Shared power to vote or to direct the vote See row 6 of the cover page.

    (iii) Sole power to dispose or to direct the disposition of See row 7 of the cover page.

    (iv) Shared power to dispose or to direct the disposition of See row 8 of the cover page.

    Percent of class is based on (i) the number of shares held by CVF as of February 29, 2024 and (ii) the number of shares of common stock outstanding as of April 26, 2024 (58,138,159 shares) as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 30, 2024. However, as of October 24, 2024, the number of shares of common stock outstanding as reported by the Issuer in its most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 28, 2024 is 58,544,158 and, as a result, the Reporting Persons now hold 4.97% of the class represented by the amount in Row (9). Accordingly, as of the date hereof, the Reporting Persons have ceased to be the beneficial owners of more the 5 percent of the class of securities represented by the amount in Row (9).

     

    Item 5.

    Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

    Dissolution of a group requires a response to this item.

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications

    Not applicable


    Signatures

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    CVF, LLC
    By:   HCC Manager LLC
    Its:   Managing Member
    By:  

    /s/ Richard H. Robb

    Name:   Richard H. Robb
    Title:   Executive Vice President
    Date:   11/7/2024
    HCC Manager LLC
    By:  

    /s/ Richard H. Robb

    Name:   Richard H. Robb
    Title:   Executive Vice President
    Date:   11/7/2024
    Get the next $NARI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NARI

    DatePrice TargetRatingAnalyst
    12/17/2024$75.00Outperform
    Oppenheimer
    9/18/2024$50.00Hold
    Stifel
    9/3/2024$47.00Market Perform
    Leerink Partners
    8/9/2024$68.00Buy
    Deutsche Bank
    7/25/2024Outperform
    William Blair
    7/18/2024Buy → Hold
    Needham
    2/29/2024$85.00 → $55.00Overweight → Neutral
    Piper Sandler
    1/23/2024$72.00Buy
    Needham
    More analyst ratings

    $NARI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Warner Robert Keith closing all direct ownership in the company (SEC Form 4)

      4 - Inari Medical, Inc. (0001531048) (Issuer)

      2/19/25 8:26:35 PM ET
      $NARI
      Medical/Dental Instruments
      Health Care
    • Chief Medical Officer Tu Thomas was granted 7,406 shares, closing all direct ownership in the company (SEC Form 4)

      4 - Inari Medical, Inc. (0001531048) (Issuer)

      2/19/25 8:22:46 PM ET
      $NARI
      Medical/Dental Instruments
      Health Care
    • Director Szyman Catherine M. closing all direct ownership in the company (SEC Form 4)

      4 - Inari Medical, Inc. (0001531048) (Issuer)

      2/19/25 8:20:54 PM ET
      $NARI
      Medical/Dental Instruments
      Health Care

    $NARI
    Leadership Updates

    Live Leadership Updates

    See more
    • Kadant Set to Join S&P SmallCap 600

      NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name      Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about

      2/13/25 5:54:00 PM ET
      $KAI
      $NARI
      $SPGI
      $SYK
      Industrial Machinery/Components
      Industrials
      Medical/Dental Instruments
      Health Care
    • Masimo Announces Leadership Transition

      Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

      1/21/25 4:00:00 PM ET
      $MASI
      $NARI
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

      Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

      5/30/24 4:00:00 AM ET
      $ALC
      $NARI
      $OCS
      $RXST
      Ophthalmic Goods
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations

    $NARI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

      Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk

      2/19/25 8:30:00 AM ET
      $NARI
      $SYK
      Medical/Dental Instruments
      Health Care
    • Kadant Set to Join S&P SmallCap 600

      NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name      Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about

      2/13/25 5:54:00 PM ET
      $KAI
      $NARI
      $SPGI
      $SYK
      Industrial Machinery/Components
      Industrials
      Medical/Dental Instruments
      Health Care
    • Masimo Announces Leadership Transition

      Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

      1/21/25 4:00:00 PM ET
      $MASI
      $NARI
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments

    $NARI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Inari Medical Inc.

      SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)

      11/8/24 2:17:22 PM ET
      $NARI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Inari Medical Inc.

      SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)

      11/8/24 10:29:30 AM ET
      $NARI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Inari Medical Inc.

      SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)

      11/7/24 4:49:55 PM ET
      $NARI
      Medical/Dental Instruments
      Health Care

    $NARI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Inari Medical Inc.

      15-12G - Inari Medical, Inc. (0001531048) (Filer)

      3/3/25 6:06:19 AM ET
      $NARI
      Medical/Dental Instruments
      Health Care
    • SEC Form 25-NSE filed by Inari Medical Inc.

      25-NSE - Inari Medical, Inc. (0001531048) (Subject)

      2/19/25 9:11:12 AM ET
      $NARI
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Inari Medical Inc.

      S-8 POS - Inari Medical, Inc. (0001531048) (Filer)

      2/19/25 9:07:02 AM ET
      $NARI
      Medical/Dental Instruments
      Health Care

    $NARI
    Financials

    Live finance-specific insights

    See more

    $NARI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

      Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk

      2/19/25 8:30:00 AM ET
      $NARI
      $SYK
      Medical/Dental Instruments
      Health Care
    • Inari Medical Reports Third Quarter 2024 Financial Results

      IRVINE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2024. Third Quarter Financial and Recent Business Highlights Generated revenue of $153 million in Q3 of 2024, up 21% over the same quarter of last year.GAAP operating loss was $13.6 million in Q3 of 2024, compared to a $2.1 million operating income in the same quarter of last year.Non-GAAP operating loss was $0.4 million in Q3 of 2024, compared to a $4.8 million non-GAAP operating income in t

      10/28/24 4:05:00 PM ET
      $NARI
      Medical/Dental Instruments
      Health Care
    • Inari Medical to Announce Third Quarter 2024 Financial Results

      IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its third quarter 2024 financial results on Monday, October 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar may be acc

      10/7/24 4:05:00 PM ET
      $NARI
      Medical/Dental Instruments
      Health Care
    • Milder Donald B bought $2,998,063 worth of shares (56,100 units at $53.44) (SEC Form 4) (Amendment)

      4/A - Inari Medical, Inc. (0001531048) (Issuer)

      5/31/24 4:54:38 PM ET
      $NARI
      Medical/Dental Instruments
      Health Care
    • Milder Donald B bought $2,998,063 worth of shares (56,100 units at $53.44) (SEC Form 4)

      4 - Inari Medical, Inc. (0001531048) (Issuer)

      11/8/23 5:48:54 PM ET
      $NARI
      Medical/Dental Instruments
      Health Care

    $NARI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Inari with a new price target

      Oppenheimer initiated coverage of Inari with a rating of Outperform and set a new price target of $75.00

      12/17/24 7:53:14 AM ET
      $NARI
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on Inari with a new price target

      Stifel initiated coverage of Inari with a rating of Hold and set a new price target of $50.00

      9/18/24 7:45:45 AM ET
      $NARI
      Medical/Dental Instruments
      Health Care
    • Leerink Partners initiated coverage on Inari with a new price target

      Leerink Partners initiated coverage of Inari with a rating of Market Perform and set a new price target of $47.00

      9/3/24 8:10:13 AM ET
      $NARI
      Medical/Dental Instruments
      Health Care